ライフサイエンスコーパス: noncarrier

1 eeping infants (60 epsilon4 carriers and 102 noncarriers).

2 oncarriers, respectively, compared with PiB- noncarriers).

3 fined by APOE genotype (epsilon4 carriers vs noncarriers).

4 haptoglobin (Hp) 1-1 genotype compared with noncarriers.

5 for APOE epsilon4 carriers and 64 years for noncarriers.

6 cosahexaenoic acid (DHA) supplement than are noncarriers.

7 earlier onset age despite being leaner than noncarriers.

8 ormal apolipoprotein E4 (APOE4) carriers and noncarriers.

9 2.34; 95% CI, 1.05-5.22) in comparison with noncarriers.

10 arkinson pathology in TREM2 R47H carriers vs noncarriers.

11 diovascular or other health benefits than do noncarriers.

12 les have greater risk of kidney disease than noncarriers.

13 respectively, and 56 (49-66) nmol/ml/min for noncarriers.

14 s (hereafter referred to as carriers) and 23 noncarriers.

15 epsilon4 allele and the other involving 1331 noncarriers.

16 h hemoglobin C trait, and 234 of 8927 (2.6%) noncarriers.

17 in APOE epsilon4 allele carriers but not in noncarriers.

18 line in eGFR, and albuminuria, compared with noncarriers.

19 ALT case incidence between HLA carriers and noncarriers.

20 erozygotes who carry 2 PARKIN mutations with noncarriers.

21 2% is explained by HbA1c levels among Hp 1-1 noncarriers.

22 RD, 6.1% [95% CI, 1.4%-13.0%]) compared with noncarriers.

23 exhibited higher PIB retention compared with noncarriers.

24 ngest effect being observed in APOE-epsilon4 noncarriers.

25 unger (P = .004) at time of examination than noncarriers.

26 s with SCT and 4.0 per 1000 person-years for noncarriers.

27 polipoprotein E (APOE) epsilon4 carriers and noncarriers.

28 tively, and 37.9 (30.5-43.7) nmol/ml/min for noncarriers.

29 inical feature between mutation carriers and noncarriers.

30 om onset compared with asymptomatic mutation noncarriers.

31 egulation in serum samples from carriers and noncarriers.

32 nced episodic memory performance relative to noncarriers.

33 e in patients with rare variants of MC4R and noncarriers.

34 riers were compared with sex- and age-paired noncarriers.

35 y composition between S. aureus carriers and noncarriers.

36 ain amyloid burden relative to APOE epsilon4 noncarriers.

37 the clinical characteristics of carriers and noncarriers.

38 tastases at diagnosis (P = .005) than PCa in noncarriers.

39 had a larger hippocampal volume relative to noncarriers.

40 was significantly higher in carriers than in noncarriers.

41 have lower brain amyloid burden relative to noncarriers.

42 e in apolipoprotein E (APOE) epsilon4 allele noncarriers.

43 nce ratios (SIRs) of cancer for carriers and noncarriers.

44 from high-dose statin therapy compared with noncarriers.

45 ctional connectivity in APOE epsilon4 allele noncarriers.

46 T had 366 prediagnosis mutation carriers and noncarriers.

47 opidogrel can address HTPR only in CYP2C19*2 noncarriers.

48 iter was observed between 8055T carriers and noncarriers.

49 ele were not at increased risk compared with noncarriers.

50 herapy, in terms of CVD risk reduction, than noncarriers.

51 enefit from high-dose statin therapy than do noncarriers.

52 included 640 APOB R3527Q carriers and 4,683 noncarriers.

53 carriers had TNBC compared with only 12% of noncarriers.

54 d-function CYP2C19 alleles, as compared with noncarriers.

55 to become abnormal in both APOE carriers and noncarriers.

56 levels were more prominent in APOE epsilon 4 noncarriers.

57 elapse-free and overall survival compared to noncarriers.

58 es of clinical misdiagnosis for carriers vs. noncarriers.

59 carriers of the 719Arg allele compared with noncarriers.

60 lobe (MTL) pathology and poorer memory than noncarriers.

61 ores at autopsy, even among APOE varepsilon4 noncarriers.

62 ated with smaller hippocampal volume than in noncarriers.

63 tion cohort of 446 V617F carriers vs 169 021 noncarriers.

64 verely affected in mutation carriers than in noncarriers.

65 s and to provide appropriate reassurances to noncarriers.

66 n carriers and 5.1% (95% CI, 4.5 to 5.7) for noncarriers.

67 activity and nigrostriatal function than PD noncarriers.

68 370S and 56 severe mainly p.L444P) and 2,641 noncarriers.

69 wer risk of coronary artery disease than did noncarriers.

70 , were similar between mutation carriers and noncarriers.

71 ss (P=4x10(-)(14)) in carriers compared with noncarriers.

72 0.001) and death (HR = 1.85; p = 0.002) than noncarriers.

73 01 [30.6%]; P = .008) compared with the 1498 noncarriers.

74 as stronger in APOEepsilon4 carriers than in noncarriers.

75 mong carriers of the E40K variant than among noncarriers.

76 ly to have coronary artery disease than were noncarriers.

77 ignificantly greater median amyloid PET than noncarriers.

78 cognitively unimpaired mutation carriers and noncarriers.

79 rriers] and 14,727 participants without SCT [noncarriers]).

80 ratios (mean [SD]: carriers, 0.32 [0.06] and noncarriers, 0.21 [0.03]; P < .001), as well as less mem

81 on carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P < .001).

82 to <30, and >/=30 ng/mL) and risk genotype (noncarrier, 1 risk allele, or 2 risk alleles).

83 63 years) was more frequent in carriers than noncarriers (10/33 vs. 3/37, p = .029), as well as the p

84 terminal pro-brain natriuretic peptide, than noncarriers (1194 participants), although carriers had a

85 1247 SCT carriers [19.2%] vs 1994 of 14,722 noncarriers [13.5%]) had CKD, 1298 (140 of 675 SCT carri

86 of 675 SCT carriers [20.7%] vs 1158 of 8481 noncarriers [13.7%]) experienced incident CKD, 1719 (150

87 s (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P < .001) and Abeta1-42:A

88 tality between carriers (41 deaths, 33%) and noncarriers (1382 deaths, 37%; age- and sex-stratified h

89 h erosions of the hands and feet were 48% of noncarriers (150/314) of valine at position 11, 61% of h

90 of 665 SCT carriers [22.6%] vs 1569 of 8249 noncarriers [19.0%]) experienced decline in eGFR, and 13

91 of 485 SCT carriers [31.8%] vs 1168 of 5947 noncarriers [19.6%]) had albuminuria during the study pe

92 Three of 12 noncarriers (25%) from the PSEN1 A79V family are potenti

93 Overall, 71.5% were noncarriers, 26.3% had 1 reduced-function CYP2C19 allele

94 nificantly higher risk of MACE compared with noncarriers (30.6% vs. 11.4%; hazard ratio: 2.88, 95% CI

95 d ratio, 1.16 [95% CI, 1.03-1.31], P = .01) (noncarriers: 319 deaths in 1398 patients over 17,196 per

96 iant carriers (124 participants [3%]) versus noncarriers (3732 participants).

97 Twenty-eight noncarriers (42%; age, 10 +/- 4 years) served as control

98 erall survival was 36% (95% CI, 34%-38%) for noncarriers, 44% (95% CI, 40%-48%) for BRCA1 carriers, a

99 te a similar mean pulmonary artery pressure (noncarriers 54+/-15 versus mutation carriers 55+/-9 mm H

100 nosis was younger for mutation carriers than noncarriers (54.3 v 62.3 years; P < .01), with five carr

101 as earlier in GBA1 mutation carriers than in noncarriers (63.5 vs 68.9 years; P < .001), with higher

102 apy (OR, 1.14 [95% CI, 1.01-1.30], P = .04) (noncarriers: 78% [439/561 patients] with moderate or goo

103 rticipated in multiple surveys: 71% remained noncarriers, 8% cleared carriage, 15% remained carriers,

104 icipants (28 Hp 1-1 carriers [12.5%] and 196 noncarriers [87.5%]) from the Israel Diabetes and Cognit

105 (SD) age was 40.06 (8.92) years; of the 156 noncarriers, 87 (55.7%) were women, and the mean (SD) ag

106 infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7).

107 rt disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7).

108 ear CSS and MFS were significantly higher in noncarriers (96% v 82%; MVA P = .01; HR = 2.6%; and 93%

109 ad a lower level of non-HDL cholesterol than noncarriers, a difference of 15.3 mg per deciliter (0.40

110 tality between V122I TTR allele carriers and noncarriers, a finding that contrasts with prior observa

111 the rs3746266 G allele had a lower BMI than noncarriers (AA genotype) (sample 1, P = .001; sample 2,

112 Relative to noncarriers, ADRA2b deletion carriers showed higher leve

113 cted family members (referred to as familial noncarriers; age range, 1-46 years; mean age, 11.7 years

114 e assessed in 18 PSEN1 E280A carriers and 19 noncarriers aged 9 to 17 years from a Colombian kindred

115 r the right precuneus were -0.590 [0.50] for noncarriers and -0.087 [0.38] for carriers; P < .005 unc

116 ] parameter estimates were 0.038 [0.070] for noncarriers and 0.190 [0.057] for carriers), as well as

117 A total of 100 APOE4 noncarriers and 100 APOE4 carriers had the primary clini

118 ulations segregating p.Y111C and p.R518X (74 noncarriers and 110 KCNQ1 mutation carriers, whereof 13

119 African LQTS-type 1 founder population (181 noncarriers and 168 mutation carriers) carrying the iden

120 HR of 1.17 (95% CI: 0.85, 1.61) in the ApoE4 noncarriers and an HR of 0.93 (95% CI: 0.50, 1.72) in th

121 HR of 1.04 (95% CI: 0.89, 1.22) in the ApoE4 noncarriers and an HR of 0.95 (95% CI: 0.73, 1.25) in th

122 icker corpora callosa compared with familial noncarriers and population control participants (16%; P

123 most salient findings compared with familial noncarriers and population control participants were rec

124 zed based on their genotype (carriers versus noncarriers) and phenotype (extensive, intermediate, and

125 tus, reduced in APOEepsilon4 carriers versus noncarriers, and associated with CSF biomarkers of AD.

126 orty-two percent of the child relatives were noncarriers, and repeat clinical follow-up could be safe

127 Relative to noncarriers, APOE-4 carriers demonstrated an accelerated

128 ts, representing both S. aureus carriers and noncarriers at three nasal sites (anterior naris, middle

129 kely that carriers can be discriminated from noncarriers based solely on phenotypical characteristics

130 beta = 0.18, 95%CI: -0.41, 0.78) compared to noncarriers (beta = 1.25, 95%CI: 0.58, 1.93).

131 nced memory for negative stimuli in deletion noncarriers but had no significant effect in deletion ca

132 a responders to the DHA supplement than were noncarriers but only in the high-BMI group.

133 g these rare variants differ clinically from noncarriers by an earlier age at symptom onset, higher p

134 We estimated breast cancer risks for noncarriers by using a population-based sample of patien

135 Compared with noncarriers, carriers had median differences in 1-year c

136 Compared with noncarriers, carriers of 4 risk alleles of rs10741657 an

137 Compared with noncarriers, carriers of PTV at CETP displayed higher hi

138 Compared with noncarriers, carriers of PTV at CETP had higher high-den

139 Compared to noncarriers, carriers of the 923Val and/or 460Arg varian

140 ln carriers vs 874.0 and 946.7 microg/mL for noncarrier cases and controls, respectively.

141 eu carriers vs 302.4 and 283.0 microg/mL for noncarrier cases and controls, respectively.

142 eu131Arg carriers vs 27.2 and 30.4 mug/mL in noncarrier cases and controls, respectively; both P < .0

143 (10.7 microg/mL vs 6.6 and 6.1 microg/mL in noncarrier cases and controls, respectively; P < .001).

144 f 88 mutation carriers and 82 (51.2%) of 160 noncarriers chose bilateral mastectomy (P < .001).

145 Compared with noncarriers, cognitively unimpaired mutation carriers ha

146 for negative stimuli compared with deletion noncarriers, consistent with prior studies.

147 a DHA-rich supplement in APOE4 carriers and noncarriers consuming a high-saturated fat diet (HSF die

148 d with carriers, stimulated whole blood from noncarriers contained on average 60% more interferon gam

149 x best characterized EEV-related activity in noncarriers, contributions of an additional VMPFC pathwa

150 d characteristics compared with the familial noncarrier control group.

151 vated in ApoE4 allele carriers compared with noncarrier controls.

152 115 (38.5%) first-degree relatives who were noncarrier controls.

153 er BP response to hydrochlorothiazide versus noncarriers (Delta systolic BP/Delta diastolic BP: -12.3

154 Tc prolongation in mutation carriers than in noncarriers, demonstrating synergistic effects of innate

155 is variant had higher uromodulin levels than noncarriers did (geometric means 10.24, 14.05, and 17.67

156 lier diagnosis, as well as using exclusively noncarrier donors and achieving complete donor chimerism

157 ions have decreased fat intake compared with noncarriers (DRD4 7+ mean, 29.03% of calories derived fr

158 eased fat intake compared with girls who are noncarriers (DRD4 7+ mean, 33.95% of calories derived fr

159 uals carrying an MC4R mutation compared with noncarriers during childhood but not during adulthood.

160 ity, but IQ scores were 26 points lower than noncarrier family members on average.

161 ions of a family with late-onset ADAD and 12 noncarrier family members were followed up at the Knight

162 n = 1223) vs the remaining controls who were noncarriers for V617F (n = 252 140).

163 rriers showed a more favorable survival than noncarriers (for BRCA1: hazard ratio [HR], 0.78; 95% CI,

164 senilin 1 (PSEN1)E280A mutation carriers and noncarriers from the world's largest known autosomal dom

165 riability in brain amyloid deposition in the noncarrier group relative to risk carriers, an effect ex

166 white matter MWF and GMV in the carrier and noncarrier groups and characterized their associations w

167 The carrier and noncarrier groups were matched for age, gestational dura

168 re compared in the APOE epsilon4 carrier and noncarrier groups.

169 l sclerosis (61.5%), whereas only 145 of 612 noncarriers had positive family history (23.7%; p<.00000

170 eir family-specific BRCA1 or BRCA2 mutation (noncarriers) have a five-fold increased risk of breast c

171 =5.2x10(-)5) in contrast to no difference in noncarriers (hazard ratio, 0.96; 95% confidence interval

172 riers was two to three times higher than for noncarriers (hazard ratios, 3.31 [95% CI, 2.41 to 4.55;

173 el and prasugrel in the 18 (56.3%) CYP2C19*2 noncarriers (HTPR in 12.5% versus 0, P=0.274), whereas i

174 e heterozygous (ID genotype), and 7 who were noncarriers (II genotype) for assessment of adipose hist

175 ognitive decline among CLU risk carriers and noncarriers in individuals who remained cognitively norm

176 in E (APOE) epsilon4 allele carriers than in noncarriers in participants (mean [SD], 1.66 [0.41] vs 1

177 and 6-month survival advantage compared with noncarriers in patients with resected disease, with an a

178 iers had lower MWF and GMV measurements than noncarriers in precuneus, posterior/middle cingulate, la

179 c fat content was found between carriers and noncarriers in the Dallas Heart Study.

180 were greater for FTO risk carriers than for noncarriers in the level 3 group [-2.28 kg (95% CI: -3.0

181 of decline in memory performance relative to noncarriers in the presymptomatic stages of disease prog

182 to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, dos

183 ight-independent resolution of diabetes than noncarriers, indicating a role for MC4Rs in the effects

184 ower in APOE epsilon4 carriers compared with noncarriers irrespective of diagnostic group (cohort A).

185 iers was 80.9% (95% CI, 75.4% to 86.4%); for noncarriers, it was 82.2% (95% CI, 80.5% to 83.7%).

186 4.7% female) and 204 eyes of 102 age-matched noncarriers (mean [SD] age, 67.1 [11.8] years; 54.9% fem

187 chieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PR

188 dentified variants (n = 177) and age-matched noncarriers (n = 157).

189 C9ORF72 mutation (n = 10) were compared with noncarriers (n = 19) and a healthy control group (n = 35

190 s (n = 98) had a 1.81-kg/m(2) lower BMI than noncarriers (n = 226; P < .0001).

191 We identified carriers (N = 20) and matched noncarriers (N = 25) for this allele in the population-b

192 aging, and cognitive testing on aging APOE-4 noncarriers (n = 30; mean age = 63.8+/-8.3) and APOE-4 c

193 in G allele carriers (n = 25) compared with noncarriers (n = 48; P < .0001), explaining 9% of BMI va

194 controls (n=6), mutation carriers (n=5), and noncarriers (n=11).

195 Compared with noncarriers (n=389), children with genomic disorders (n=

196 c mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12).

197 ntly different between mutation carriers and noncarriers (no left ventricular remodeling or fibrosis,

198 GBA noncarrier non-PD spouse control participants were recru

199 on was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval,

200 In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were

201 re reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, resp

202 evidence of increased breast cancer risk for noncarriers of identified mutations compared with FDRs f

203 cerols (TAGs) between carriers compared with noncarriers of PNPLA3(I148M) gene variant display defici

204 rriers of the PPARG G allele (rs1801282) and noncarriers of PPARGC1A A allele (rs8192678) had 21 and

205 Differences between carriers and noncarriers of rare variants in age at onset of symptoms

206 ment were also compared between carriers and noncarriers of specified MHC variants.

207 In TNT, for noncarriers of the 719Arg allele, the HR for high- versu

208 Carriers compared with noncarriers of the ADRA2B deletion variant exhibited a s

209 fMRI results indicated that, whereas noncarriers of the ADRA2B deletion variant showed increa

210 Noncarriers of the APOE epsilon4 allele with severe CAA

211 es were repeated separately for carriers and noncarriers of the APOE epsilon4 allele.

212 In noncarriers of the CR1 risk allele, APOE epsilon4 indivi

213 mporal lobe cortices in healthy carriers and noncarriers of the KIBRA T-allele (rs17070145).

214 There have been claims that noncarriers of the KIF6 719Arg variant receive little be

215 In our data, carriers and noncarriers of the p.E508K mutation with type 2 diabetes

216 mpare the frequency of AF among carriers and noncarriers of these rare variants.

217 They performed better than noncarriers on the Mini-Mental State Examination (P = .0

218 silon4 carriers had greater progression than noncarriers on the partner (1.10, SE=0.44, P<.012) and s

219 ate analyses, carriers performed better than noncarriers on the UPDRS-III (P = .02) and on tests of a

220 g potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin o

221 f 23 BRCA2 carriers and 53 (22%) of 237 BRCA noncarriers (P < .001).

222 carriers but in only two neonatally screened noncarriers (P < .001); six patient cases were identifie

223 They had lower serum lipid levels than noncarriers (P < 0.05), had more-severe steatosis, necro

224 k for PD was higher in patients with GD than noncarriers (P = .008, log-rank test) and in heterozygot

225 08, log-rank test) and in heterozygotes than noncarriers (P = .03, log-rank test), but it did not rea

226 or carriers was 28.2 (5.5) vs 29.3 (5.3) for noncarriers (P = .19).

227 s 45.3 years (11.2) vs 47.5 years (11.5) for noncarriers (P = .49) and the mean (SD) BMI for carriers

228 in Mini-Mental State Exam scores compared to noncarriers (p = 0.0009).

229 eductions in TC and LDL cholesterol than did noncarriers (P = 0.036 and 0.039, respectively), whereas

230 0.0007) versus a 0.009-mL decrease in Hp 1-1 noncarriers (P = 0.047), after adjusting for total intra

231 rsion was similar between APOE4 carriers and noncarriers (p = 0.321), indicating that the non-Cp copp

232 t had higher NFATC2 expression compared with noncarriers (P = 1.1 x 10(-3) and 0.03, respectively).

233 n the carriers were 39% lower than levels in noncarriers (P<1x10(-20)), and circulating levels of APO

234 s disease had poorer cognitive function than noncarriers (P=0.003).

235 ter (0.31 mmol per liter) lower than that in noncarriers (P=0.04).

236 C3 in carriers were 46% lower than levels in noncarriers (P=8x10(-10)).

237 gate carrier, and absent from the unaffected noncarrier parent in 1 DBA family.

238 als with de novo 16p11.2 deletions and their noncarrier parents and siblings from the Simons Variatio

239 ent anticipation in which rare variants from noncarrier parents may attenuate constitutive resistance

240 carriers (heterozygotes, n = 694), and among noncarriers (parents of non-PD, non-GD control participa

241 6 versus 116.1 to 125.7 mg/dL) compared with noncarrier participants.

242 In healthy S aureus carriers and noncarriers, peripheral blood T cells elaborated TH2 cyt

243 FI levels correlated with C3b degradation in noncarriers (R2 = 0.35 and R2 = 0.31, respectively; both

244 or prasugrel (genotyping with prasugrel) and noncarriers receiving clopidogrel.

245 1 (n = 909) or BRCA2 (n = 304) and from 2666 noncarriers recruited and followed up at variable times

246 by 26.3 points between proband carriers and noncarrier relatives and a lower mean FSIQ score (16.2-1

247 ers (80 symptomatic and 38 asymptomatic), 58 noncarrier relatives from 40 families, and 200 healthy d

248 We found no evidence of their noncarrier relatives having an increased risk of any can

249 nce of an increased risk of cancer for their noncarrier relatives.

250 letion on clinical traits by comparison with noncarrier relatives.

251 tures that discriminate between carriers and noncarriers remain unclear.

252 I, 0.9-2.8, for PiB+ APOE4 carriers and PiB+ noncarriers, respectively, compared with PiB- noncarrier

253 among heterozygotes, and 0.7% and 2.1% among noncarriers, respectively.

254 were compared between mutation carriers and noncarriers.RESULTS Of 86 patients with SNs, 25 (29%) ha

255 ECG data from mutation carriers and noncarriers revealed that the K422T mutation per se had

256 e carriers had an increased risk of 7.7%; in noncarriers, risk was reduced to 0.5%, comparable to ALT

257 study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) wit

258 ly (n = 30) who were either carriers (T+) or noncarriers (T-) of the DISC1 translocation.

259 CSS was significantly longer in noncarriers than in carriers (15.7 v 8.6 years, multivar

260 ese results support the practice of advising noncarriers that they do not have any increase in breast

261 r CHEK2*1100delC heterozygotes compared with noncarriers, the age- and sex-adjusted hazard ratios wer

262 elated with BMI in APOE4 carriers but not in noncarriers, the following 2 groups were formed accordin

263 ps and cognitively normal APOE4 carriers and noncarriers; the sample sizes needed to detect attenuate

264 that among BRCA1 mutation carriers, as among noncarriers, there are unique characteristics associated

265 ride levels that were lower than those among noncarriers; these mutations were also associated with p

266 vival is reduced in GBA carriers compared to noncarriers; this seems to be partially independent from

267 n was performed on all mutation carriers and noncarriers to establish clinical and genetic cosegregat

268 AD51 mutation carriers were more likely than noncarriers to have a family history of ovarian cancer (

269 carriers were significantly more likely than noncarriers to have an intensification of their antiplat

270 ant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio,

271 ore cost-effective but increases exposure of noncarriers to mupirocin and the risk of resistance to m

272 n BRCA1 mutation carriers, as well as within noncarriers, triple-negative receptor status was associa

273 interval: 17% to 31%; p = 4.6 x 10(-)(9)) in noncarriers (Trp/Trp).

274 er on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean,

275 r CHEK2*1100delC heterozygotes compared with noncarriers was 2.08 (95% CI, 1.51 to 2.85) for breast c

276 arker changes that distinguish carriers from noncarriers was estimated using best-fitting regression

277 ole blood from 43 persistent carriers and 49 noncarriers was stimulated with viable S. aureus T-helpe

278 When we compared p.P50T/AKT2 carriers to noncarriers, we found a 39.4% reduction in whole-body GU

279 usted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P

280 cteristics between rare variant carriers and noncarriers were analyzed using univariable generalized

281 e, 0) and between APOE epsilon4 carriers and noncarriers were compared.

282 ios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression

283 A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis.

284 ent on measures of memory retention, whereas noncarriers were more impaired on tests of working memor

285 No differences between LypW carriers and noncarriers were observed in virus-specific CD8(+) T-cel

286 Forty-one APOE4 carriers and 41 noncarriers were prospectively recruited and consumed an

287 arriers of mild mutations overlapped with PD noncarriers, whereas carriers of severe mutations were c

288 d 167 prediagnosis mutation carriers and 156 noncarriers, whereas COHORT had 366 prediagnosis mutatio

289 men that was two times as high as that among noncarriers, which indicates that genetic variation in P

290 st risk of incident MCI for APOE varepsilon4 noncarriers who engage in mentally stimulating activitie

291 ry performance between CLU risk carriers and noncarriers who remained cognitively normal.

292 nth-old infants (23 epsilon4 carriers and 36 noncarriers), who remained asleep during the scanning se

293 The referent group was noncarriers with adequate vitamin D status (>/=30 ng/mL)

294 PREMM5 distinguished carriers from noncarriers with an AUC of 0.81 (95% CI, 0.79 to 0.82),

295 antly worse memory scores than those of both noncarriers with high-folate and del/del carriers with n

296 ter cognitive and motor performance than did noncarriers with long disease duration, suggesting slowe

297 Of the 37 APOE4 noncarriers with minimal neuritic plaques, 16 individual

298 examine WMH differences between carriers and noncarriers with respect to EYO.

299 e-third of apolipoprotein E epsilon4 (APOE4) noncarriers with the clinical diagnosis of mild to moder

300 In this study, more than one-third of APOE4 noncarriers with the primary clinical diagnosis of mild